- The acquisition expands the anti-infectives pipeline with the addition of Amplyx’s P-II candidate, Fosmanogepix (APX001) which is being evaluated in both IV and oral formulations for the treatment of patients with invasive fungal infections
- Pfizer also retains ownership of the Amplyx early-stage pipeline, including antiviral (MAU868) and antifungal (APX2039) therapies. The acquisition follows an initial equity investment by Pfizer in December 2019 as part of Amplyx’s Series C funding
- Fosmanogepix has demonstrated broad-spectrum activity in-vitro and showed wide distribution to various tissues, including brain, lung, kidney, and eye
Click here to read full press release/ article | Ref: Pfizer | Image: PRNewswire
The post Pfizer Acquires Amplyx to Expand its Infectious Disease Portfolio first appeared on PharmaShots.